The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis (UCHAT)

November 7, 2019 updated by: Raymond Cross, University of Maryland, Baltimore
The purpose of this study is to determine if home automated telemanagement improves bowel symptoms, quality of life, compliance with medications, and health care utilization compared to best available care in patients with ulcerative colitis.

Study Overview

Detailed Description

Ulcerative colitis (UC) is a common inflammatory condition of the bowels that results in bloody diarrhea, abdominal pain, and lack of control of bowel movements. UC is a chronic medical condition that causes frequent episodes of symptoms ("flares") followed by symptom-free intervals. Although drugs are available to treat the symptoms, there are obstacles to successful treatment. Because patients need to take medications continuously to avoid flares, compliance with drugs can difficult. Monitoring the symptoms of UC is also challenging, because flares are sporadic and often do not occur at the time of routine office visits. This can result in treatment delays. Although the drugs used to treat colitis are effective, they have side effects which can decrease compliance and quality of life. Patient's knowledge of the disease can also be poor, which can affect many aspects of care.

Telemanagement systems are telemedicine systems that are designed to (1) assist physicians in monitoring their patients, (2) assist physicians in following current guidelines, (3) help patients follow self-care plans, and (4) deliver educational facts to patients. Telemedicine systems have been used in diseases similar to UC and have improved outcomes. We designed a telemanagement system specifically for patients with inflammatory bowel disease (IBD HAT) and found that IBD HAT was easy to use, was accepted by patients, and improved various aspects of patient care including patient knowledge, quality of life, and bowel symptoms.

The purpose of the study is to determine if a home telemanagement system for patients with UC (UC HAT) improves clinical outcomes compared to routine care. Patients with UC will be identified from the University of Maryland IBD program and the gastroenterology clinic of the VA Maryland Health Care System, Baltimore. A computer program will assign interested patients by chance to either the UC HAT or the routine care group. Patients in the UC HAT group will be asked to complete self-testing each week at home using the system. The home-unit consists of a laptop computer and electronic weight scale. After turning on the computer, patients answer questions about their bowel symptoms, medication side effects, and compliance with medications. The home-unit then prompts subjects to measure their weight on the scale. Subjects then receive an educational "tip of the day". The following session, subjects answer an educational question that relates to the tip. After self-testing is completed, the results are transmitted via a phone line to our secure server. The results are made available immediately for review on the physician's web portal. Based on the responses to the symptom diary, side effect questions, medical compliance, and body weight, electronic alerts and action plans can be generated. An alert is sent electronically to the study coordinator, who then reviews the information and discusses the findings with the principal investigator and the patient's medical provider. Changes in patient management can be made if appropriate. An action plan is created for each patient at the first visit and contains a list of tasks for patients to start immediately after self-testing if certain criteria are met. Patients still undergo regularly scheduled clinical visits as prescribed by their medical provider.

Patients assigned to the routine care group will undergo scheduled follow up clinical visits, telephone follow up, and receive educational fact sheets about their disease. This is considered routine care at our centers. All patients will undergo research visits every 3 months for one year. Patients will complete a series of questionnaires at each visit that measure the patient's disease activity, quality of life, IBD knowledge, medical compliance, and other parameters. Emergency room visits and hospitalizations will also be measured. A blood draw is required at each study visit.

We think that UC HAT will improve the monitoring of bowel symptoms and medication side effects and improve medical compliance. These improvements should result in decreased bowel symptoms, improved quality of life, and decreased urgent care visits and hospitalizations. If UC HAT is effective, the system could be used in the IBD community to improve clinical care or be used in patients with limited access to health care.

Study Type

Interventional

Enrollment (Actual)

47

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Maryland
      • Baltimore, Maryland, United States, 21201
        • University of Maryland
      • Baltimore, Maryland, United States, 21205
        • Johns Hopkins Medical Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of ulcerative colitis confirmed by standard clinical, endoscopic, and histologic criteria

Exclusion Criteria:

  • Inability to comply with the study protocol
  • Previous colectomy with ileostomy or colectomy with ileoanal anastomosis
  • History of colonic dysplasia or colorectal cancer
  • Uncontrolled medical or psychiatric disease
  • Unable or unwilling to provide consent
  • Age less than 18 years
  • Other forms of colitis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
UC Home Automated Telemanagement
Weekly assessment with UC Home Automated Telemanagement
Active Comparator: Control
Best Available Care
Routine follow up visits and as needed telephone calls and clinic visits, written action plans, educational fact sheets from the CCFA

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical Disease Activity (Seo Index)
Time Frame: 12 months
Clinical disease activity was assessed using the Seo index. An activity index <120 represents clinical remission, whereas scores of 121-150, 151-220, and >221 correlate with mild, moderate, and severe disease respectively. The Seo index is sensitive to change, with a decrease in the index of 35 correlating with a clinical response.
12 months
Quality of Life (IBDQ)
Time Frame: 12 Months
Disease-specific quality of life was assessed using the IBD questionnaire (IBDQ). Scores for the IBDQ range from 32 to 224 with higher scores being associated with better quality of life. Score changes of 16 have been found to be significant changes when compared to baseline values.
12 Months
Percentage of Participants Adherent to Therapy
Time Frame: 12 Months
Adherence was assessed using the Morisky Medication Adherence Score, a 4 item survey in which participants self-report medication-taking behavior. Each question that is answered with a No receives a score of 1. The possible scoring range is therefore 0 to 4. Higher scores correlate with better medical adherence. For the purpose of evaluating percent of participants adherent to therapy, the variable was dichotomized to "Adherent" or "Non-adherent". Any response of Yes to one of the 4 items was scored as "Non-Adherent".
12 Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Raymond K Cross, MD,MS, University of Maryland, College Park

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2008

Primary Completion (Actual)

February 1, 2010

Study Completion (Actual)

February 1, 2010

Study Registration Dates

First Submitted

February 8, 2008

First Submitted That Met QC Criteria

February 20, 2008

First Posted (Estimate)

February 21, 2008

Study Record Updates

Last Update Posted (Actual)

November 13, 2019

Last Update Submitted That Met QC Criteria

November 7, 2019

Last Verified

November 1, 2019

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ulcerative Colitis

Clinical Trials on UC Home Automated Telemanagement

3
Subscribe